![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Jun 2009
Medivation to begin a Phase III trial of Dimebon
Medivation is sponsoring a randomized, double-Blind, placebo-controlled, Phase III trial of Dimebon in patients with mild to moderate Huntington’s Disease 24 Apr 2009
Acetylation of the HD protein
MSG-MIND researchers discover a new therapeutic target: increased acetylation enhances clearance of the HD ptotein from the nucleus. 24 Apr 2009
An ampakine upregulates BDNF
An ampakine, a modulator of glutamate receptors, reduced memory and learning problems in HD mice. 23 Apr 2009
Minocycline Phase II clinical trial results are disappointing
23 Apr 2009
CERE-120 (AAV-Neurturin) is neuroprotective in HD mouse model
Neurturin. a neurotrophic factor, protected striatal and cortical neurons in an HD mouse model. 23 Apr 2009
Disappointing results from a Phase II trial of CERE-120 for PD patients
Neurturin, a neurotrophic factor, failed to yield meaningful improvement in PD patients. 8 Apr 2009
Amarin files new drug application for AMR 101 in Europe
Ethyl-EPA remains in the drug development pipeline. 8 Apr 2009
Toxic HD protein fragments
Research continues to support the toxic fragment hypothesis. 27 Feb 2009
Warning about Reglan
Metoclopramide (Reglan) poses risks to those with HD and PD. 3 Feb 2009
The ACR-16 trial is enrolling participants
An interview with lead investigator Dr. Karl Kieburtz. All Updates for Home |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|